# Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing

> **NCT00647270** · PHASE3 · COMPLETED · sponsor: **Abbott** · enrollment: 420 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** adalimumab
- **DRUG:** Placebo
- **DRUG:** adalimumab

## Key facts

- **NCT ID:** NCT00647270
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 420 (ACTUAL)
- **Last updated:** 2011-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00647270

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00647270, "Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other Week Dosing". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00647270. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*